Literature DB >> 1898706

A case report of malignant pleural mesothelioma with long-term disease control after chemotherapy.

T Umsawasdi1, H M Dhingra, C Charnsangavej, M A Luna.   

Abstract

Long duration of responses to chemotherapy in patients with malignant pleural mesothelioma (MPM) is rare. The authors report a patient with inoperable MPM who achieved complete remission with combination chemotherapy of cyclophosphamide, doxorubicin, and cisplatin. 5-fluorouracil and mitomycin C (FM) induced another remission after recurrence of the tumor. Retreatment with FM after chemotherapy had been stopped for 20 months yielded another continuing response. The overall tumor-control time is more than 4 years. Literature reviews and the authors' results suggest that MPM may be a chemosensitive tumor in some patients. Additional evaluations of CAP, FM, and methotrexate combination regimens in this disease should be considered.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1898706     DOI: 10.1002/1097-0142(19910101)67:1<48::aid-cncr2820670110>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Pegylated liposomal doxorubicin in malignant pleural mesothelioma: a possible guardian for long-term survival.

Authors:  Paul Zarogoulidis; Maria Mavroudi; Konstantinos Porpodis; Kalliopi Domvri; Antonios Sakkas; Nikolaos Machairiotis; Aikaterini Stylianaki; Anastasios Tsiotsios; Nikolaos Courcoutsakis; Konstantinos Zarogoulidis
Journal:  Onco Targets Ther       Date:  2012-09-27       Impact factor: 4.147

Review 2.  Current therapy for malignant mesothelioma.

Authors:  W Roy Smythe
Journal:  Curr Oncol Rep       Date:  2002-07       Impact factor: 5.945

3.  Malignant pleural mesothelioma with long-term tumor disappearance of a local relapse after surgery: a case report.

Authors:  Masahiko Higashiyama; Kazuyuki Oda; Jiro Okami; Jun Maeda; Ken Kodama; Fumio Imamura
Journal:  J Med Case Rep       Date:  2009-03-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.